TY - JOUR
T1 - Multidimensional evaluation of the pain profile as prognostic factor in individuals with hip or knee osteoarthritis receiving total joint replacement
T2 - protocol of a 2-year longitudinal prognostic cohort study
AU - Florencio, Lidiane L
AU - Palacios-Ceña, María
AU - Fuensalida-Novo, Stella
AU - de-la-Llave-Rincón, Ana I
AU - Ambite-Quesada, Silvia
AU - Ortega-Santiago, Ricardo
AU - Arias-Buría, José L
AU - Cigarán-Méndez, Margarita
AU - Arendt-Nielsen, Lars
AU - Fernández-de-Las-Peñas, César
N1 - Funding The study will be funded by a research project grant (FIS PI20/00310)
from the Health Institute Carlos III and PN I+D+I 2017-2020, Spanish Government
and by the Center for Neuroplasticity and Pain - CNAP (DNRF121) at Aalborg
University (Denmark). This study will likewise be supported by The Danish
Rheumatic Association is acknowledged for the support (grant #R204-A7645).
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2023/1/19
Y1 - 2023/1/19
N2 - INTRODUCTION: Knee and hip osteoarthritis are two highly prevalent musculoskeletal pain conditions. Unsuccessful rates after hip/knee replacement range from 10% to 20%. Subjects with sensitisation manifestations are vulnerable to worse clinical outcomes. Most studies have analysed outcomes up to 1 year after surgery. The aim of this 2-year longitudinal study will be to evaluate sensory-related, psychological and psychophysical pain sensitisation manifestations and a potential epigenetic biomarker as prognostic clinical outcomes for the development of chronic postoperative pain after knee or hip replacement.METHODS AND ANALYSIS: A prospective longitudinal study with a 2-year follow-up period will be conducted. The prognostic variables will include pain, function, related-disability, anxiety, depression, quality of life, sensitisation-associated symptoms, kinesiophobia, neuropathic pain and catastrophising, and expectative of the intervention will be assessed before surgery. We will also evaluate the presence of the Val158Met polymorphism as a possible epigenetic marker. Clinical outcomes including pain, related-disability and self-perceived satisfaction, sensitisation-associated symptoms and neuropathic pain will be assessed 3, 6, 12, 18 and 24 months after surgery. These variables will be used to construct three prediction models: (1) pain and function, (2) sensitisation-associated symptomatology and (3) neuropathic pain features classifying those patients in responders and non-responders. Data from knee or hip osteoarthritis will be analysed separately. Statistical analyses will be conducted with logistic regressions.ETHICS AND DISSEMINATION: The study has been approved by the Ethics Committee of both institutions involved (Hospital Universitario Fundación Alcorcón (HUFA) 19-141 and Universidad Rey Juan Carlos (URJC) 0312201917319). Participants will sign the written informed consent before their inclusion. Study results will be disseminated through peer-reviewed publications and presentations at scientific meetings.
AB - INTRODUCTION: Knee and hip osteoarthritis are two highly prevalent musculoskeletal pain conditions. Unsuccessful rates after hip/knee replacement range from 10% to 20%. Subjects with sensitisation manifestations are vulnerable to worse clinical outcomes. Most studies have analysed outcomes up to 1 year after surgery. The aim of this 2-year longitudinal study will be to evaluate sensory-related, psychological and psychophysical pain sensitisation manifestations and a potential epigenetic biomarker as prognostic clinical outcomes for the development of chronic postoperative pain after knee or hip replacement.METHODS AND ANALYSIS: A prospective longitudinal study with a 2-year follow-up period will be conducted. The prognostic variables will include pain, function, related-disability, anxiety, depression, quality of life, sensitisation-associated symptoms, kinesiophobia, neuropathic pain and catastrophising, and expectative of the intervention will be assessed before surgery. We will also evaluate the presence of the Val158Met polymorphism as a possible epigenetic marker. Clinical outcomes including pain, related-disability and self-perceived satisfaction, sensitisation-associated symptoms and neuropathic pain will be assessed 3, 6, 12, 18 and 24 months after surgery. These variables will be used to construct three prediction models: (1) pain and function, (2) sensitisation-associated symptomatology and (3) neuropathic pain features classifying those patients in responders and non-responders. Data from knee or hip osteoarthritis will be analysed separately. Statistical analyses will be conducted with logistic regressions.ETHICS AND DISSEMINATION: The study has been approved by the Ethics Committee of both institutions involved (Hospital Universitario Fundación Alcorcón (HUFA) 19-141 and Universidad Rey Juan Carlos (URJC) 0312201917319). Participants will sign the written informed consent before their inclusion. Study results will be disseminated through peer-reviewed publications and presentations at scientific meetings.
KW - Hip
KW - Knee
KW - Surgery
KW - Osteoarthritis, Knee/surgery
KW - Prognosis
KW - Prospective Studies
KW - Humans
KW - Arthroplasty, Replacement, Knee/psychology
KW - Osteoarthritis, Hip/surgery
KW - Pain, Postoperative/surgery
KW - Quality of Life
KW - Neuralgia
KW - Longitudinal Studies
KW - Cohort Studies
U2 - 10.1136/bmjopen-2022-066745
DO - 10.1136/bmjopen-2022-066745
M3 - Journal article
C2 - 36657768
SN - 2044-6055
VL - 13
JO - BMJ Open
JF - BMJ Open
IS - 1
M1 - e066745
ER -